Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact

被引:1
|
作者
Bertuzzi, Clara [1 ]
Righi, Simona [2 ]
Motta, Giovanna [1 ]
Rossi, Maura [2 ]
Carella, Matteo [3 ,4 ]
Gabrielli, Giulia [3 ,4 ]
Facchini, Elena [5 ]
Baldassarre, Maurizio [6 ]
Prete, Arcangelo [5 ]
Zinzani, Pier Luigi [3 ,4 ]
Mascolo, Massimo [7 ]
Agostinelli, Claudio [1 ,2 ]
Sabattini, Elena [1 ]
机构
[1] IRCCS Azienda Osped Univ Bologna, Haematopathol Unit, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy
[3] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, I-40138 Bologna, Italy
[4] Univ Bologna, Dipartimento Sci Med & Chirurg, I-40138 Bologna, Italy
[5] IRCCS Azienda Osped Univ Bologna, Pediat Unit, I-40138 Bologna, Italy
[6] IRCCS Azienda Osped Univ Bologna, Unit Semeiot Liver & Alcohol Related Dis, I-40138 Bologna, Italy
[7] Univ Naples Federico II, Sch Med, Pathol Sect, Dept Adv Biomed Sci, I-80131 Naples, Italy
关键词
Hodgkin's; adolescent; microenvironment; immune-check points; COMPLEX CLASS-II; T-CELL SUBSETS; TUMOR MICROENVIRONMENT; YOUNG-ADULTS; MULTICENTER; EXPRESSION; DISEASE; NIVOLUMAB; BLOCKADE; CANCER;
D O I
10.3390/cancers16244210
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years old shows a higher disease-related mortality, and the overall prognosis is worse than in both children and adults. Objectives. We investigated the immune checkpoint inhibitors (ICPIs) therapeutic targets and specific T-regulatory and cytotoxic T-cell subsets in the subgroup of adolescent cHL patients, and we challenged their prognostic power. Methods. We retrieved formalin-fixed paraffin-embedded (FFPE) tissue of adolescent patients diagnosed with cHL and tested by immunohistochemistry the immune checkpoint molecules CTLA-4, LAG-3, PD-1, and PDL1 as well as the biological markers FOXP3 and CD8. Results. All the cases of our cohort expressed the immune checkpoint molecules CTLA-4, LAG-3, and PD-1 in microenvironment (ME), and the number of PD1+ cells was strongly associated with advanced disease, being higher in stage III/IV, indicating a possible role in the progression of cHL. A higher risk of recurrence and progression occurred in patients with lower amount of CD8+ microenvironmental T-cells at diagnosis (67.14 +/- 27.23 vs. 42.86 +/- 17.33 p = 0.032 and 65.59 +/- 26.68 vs. 37 +/- 17.45 p = 0.046, respectively). Conclusions. We showed that microenvironment of cHL in adolescent patients is enriched with potential therapeutic targets of ICPI that may be considered for therapeutic applications. Furthermore, the presence of PD-1 expressing T-cells strongly relates to advanced stage disease and a low density of CD8+ T lymphocytes is associated with recurrence and progression of disease.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Prognostic Serum Cytokines in Classical Hodgkin Lymphoma-Letter
    Coutelle, Oliver
    Buening, Hildegard
    Pluetschow, Annette
    Fuchs, Michael
    Escalona-Espinosa, Laura
    Engert, Andreas
    Hacker, Ulrich
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6633 - 6633
  • [22] MICRORNAS IN ADVANCED CLASSICAL HODGKIN LYMPHOMA: SIGNATURES WITH PROGNOSTIC SIGNIFICANCE
    Sanchez-Espiridion, B.
    Montalban, C.
    Guisado, P.
    Rodriguez, M. E.
    Canales, M.
    Alves, F. J.
    Vega, F.
    Younes, A.
    Morente, M. M.
    Tomas, J. F.
    Piris, M. A.
    Garcia, J. F.
    ANNALS OF ONCOLOGY, 2011, 22 : 152 - 152
  • [23] Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
    Martynchyk, Arina
    Chowdhury, Rakin
    Hawkes, Eliza A.
    Keane, Colm
    CANCERS, 2023, 15 (21)
  • [24] Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma
    Marri, Preethi Reddy
    Hodge, Lucy S.
    Maurer, Matthew J.
    Ziesmer, Steven C.
    Slager, Susan L.
    Habermann, Thomas M.
    Link, Brian K.
    Cerhan, James R.
    Novak, Anne J.
    Ansell, Stephen M.
    CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6812 - 6819
  • [25] Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
    Allen, Pamela B.
    Gordon, Leo I.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2017, 11
  • [26] Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents
    Daw, Stephen
    Wynn, Rob
    Wallace, Hamish
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (03) : 249 - 260
  • [27] Immune reactions in classical Hodgkin's lymphoma
    Poppema, S
    Potters, M
    Emmens, R
    Visser, L
    van den Berg, A
    SEMINARS IN HEMATOLOGY, 1999, 36 (03) : 253 - 259
  • [28] Tislelizumab for the treatment of classical Hodgkin's lymphoma
    Chen, J.
    Zhang, H.
    Zhu, L.
    Zhao, Y.
    Ding, Y.
    Yuan, Y.
    DRUGS OF TODAY, 2020, 56 (12) : 781 - 785
  • [29] PROGNOSTIC IMPACT OF AN UNBALANCED IMMUNE SYSTEM IN PATIENTS WITH CLASSICAL HODGKIN'S LYMPHOMAS
    Gaudio, F.
    Laddaga, F.
    Perrone, T.
    Mestice, A.
    Pinto, P.
    Daraia, B.
    Carluccio, V.
    Gentile, A.
    Specchia, G.
    HAEMATOLOGICA, 2015, 100 : 88 - 88
  • [30] The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis
    Carbone, Antonino
    Gloghini, Annunziata
    Caruso, Arnaldo
    De Paoli, Paolo
    Dolcetti, Riccardo
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (06) : 1233 - 1245